The company has substantially boosted its development of the new therapy for amyloid heart disease, leveraging the investigational drug. Preliminary trial results reveals significant improvements for patients affected from the serious disease. The emphasis represents researchers’ focus to managing critical healthcare needs in a cardiology arena.